Caris Life Sciences, Inc.
CAI
$24.03
-$0.79-3.18%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -637.00K | -510.00K | 81.96M | 24.33M | -71.79M |
| Total Depreciation and Amortization | 6.54M | 5.07M | 4.29M | 4.87M | 6.41M |
| Total Amortization of Deferred Charges | 299.00K | 2.62M | 605.00K | 2.46M | 7.76M |
| Total Other Non-Cash Items | 48.65M | 17.41M | 17.02M | 16.68M | 66.35M |
| Change in Net Operating Assets | -26.37M | 8.29M | -59.10M | 14.09M | -1.44M |
| Cash from Operations | 28.48M | 32.88M | 44.78M | 62.43M | 7.29M |
| Capital Expenditure | -22.08M | -10.34M | -5.09M | -7.10M | -1.39M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.12M | -- | -- | -- | -- |
| Cash from Investing | -122.19M | -10.34M | -5.09M | -7.10M | -1.39M |
| Total Debt Issued | 393.50M | -- | 0.00 | 0.00 | 27.87M |
| Total Debt Repaid | -406.35M | -40.00K | -39.00K | -23.00K | -22.00K |
| Issuance of Common Stock | 3.68M | 920.00K | 3.86M | 1.15M | 529.65M |
| Repurchase of Common Stock | -26.63M | -56.00K | -424.00K | -16.56M | -1.66M |
| Issuance of Preferred Stock | -- | -- | 0.00 | 0.00 | 121.24M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.11M | -- | 0.00 | -5.67M | 4.33M |
| Cash from Financing | -36.90M | 824.00K | 3.40M | -21.10M | 681.40M |
| Foreign Exchange rate Adjustments | -27.00K | -10.00K | -29.00K | 62.00K | 93.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -130.65M | 23.35M | 43.06M | 34.30M | 687.40M |